Found 168 clinical trials
The Project: Every Child Protocol: A Registry Eligibility Screening Biology and Outcome Study
This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
- 0 views
- 19 Feb, 2024
- 1 location
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed).
- 0 views
- 19 Feb, 2024
- 1 location
An Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to see if Daratumumab is useful for treating pediatric (subjects aged >=1 to 18 years) and young adult patients (aged 18 to 30 years) with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been …
- 0 views
- 19 Feb, 2024
- 1 location
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia
The purpose of this study is to find the maximum safe dose of nivolumab alone, and of nivolumab combined with azacitidine after reduced-intensity allogeneic peripheral blood stem cell (PBSC) transplantation. Another purpose is to see how the study drugs affect different aspects of transplant such as infection and disease response.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1 Study of Pevonedistat (MLN4924) a Cullin Ligase Inhibitor in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of pevonedistat when giving together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors or lymphoma that have come back after a period of improvement or that do not respond to treatment.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R …
- 0 views
- 19 Feb, 2024
- 1 location
A Study of Safety Tolerability and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab (either drug alone or in combination) are safe in treating adult subjects with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).
- 0 views
- 19 Feb, 2024
- 1 location